Get the Stockscreener App
1.235
2.92%
0.035
Lexicon Pharmaceuticals Inc stock is traded at $1.235, with a volume of 550.17K.
It is up +2.92% in the last 24 hours and up +68.23% over the past month.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
See More
Previous Close:
$1.20
Open:
$1.21
24h Volume:
550.17K
Relative Volume:
0.12
Market Cap:
$448.52M
Revenue:
$1.21M
Net Income/Loss:
$-177.12M
P/E Ratio:
-1.5438
EPS:
-0.8
Net Cash Flow:
$-162.37M
1W Performance:
-4.26%
1M Performance:
+68.23%
6M Performance:
+39.52%
1Y Performance:
-44.37%
1-Day Range:
$1.21
$1.25
1-Week Range:
$1.155
$1.43
52-Week Range:
$0.2836
$2.45
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Name
Lexicon Pharmaceuticals Inc
Sector
Industry
Phone
(281) 863-3000
Address
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.235 | 417.65M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.04 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
570.63 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.25 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.32 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
297.70 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-17-24 | Initiated | H.C. Wainwright | Buy |
| Apr-30-24 | Initiated | Leerink Partners | Outperform |
| Mar-07-23 | Initiated | Jefferies | Hold |
| Aug-12-22 | Initiated | Piper Sandler | Overweight |
| Jan-29-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-29-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-18-20 | Upgrade | Gabelli & Co | Hold → Buy |
| Dec-11-19 | Downgrade | Gabelli & Co | Buy → Hold |
| Nov-08-19 | Downgrade | Citigroup | Buy → Neutral |
| Sep-11-19 | Upgrade | Gabelli & Co | Hold → Buy |
| Jul-29-19 | Downgrade | Stifel | Buy → Hold |
| Mar-25-19 | Upgrade | Gabelli & Co | Sell → Hold |
| Jul-31-18 | Reiterated | Stifel | Buy |
| Feb-23-18 | Downgrade | Needham | Buy → Hold |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-01-17 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-17 | Reiterated | Wedbush | Outperform |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Aug-05-16 | Reiterated | Wedbush | Outperform |
| Aug-02-16 | Initiated | Citigroup | Buy |
| Mar-02-16 | Reiterated | Wedbush | Outperform |
| Nov-09-15 | Reiterated | Wedbush | Outperform |
| Sep-28-15 | Upgrade | Gabelli & Co | Sell → Hold |
| Sep-18-15 | Downgrade | Gabelli & Co | Hold → Sell |
| Aug-10-15 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Lexicon Pharmaceuticals Inc Stock (LXRX) Latest News
Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025 - The Manila Times
Lexicon Pharmaceuticals Scheduled to Release Q2 2025 Financial Results and Conduct Conference Call on August 6, 2025 - Quiver Quantitative
What drives Lexicon Pharmaceuticals Inc. stock pricePowerful market insights - jammulinksnews.com
Is Lexicon Pharmaceuticals Inc. a good long term investmentUnstoppable profit momentum - jammulinksnews.com
Lexicon Pharmaceuticals Inc. Stock Analysis and ForecastOver 200% growth - jammulinksnews.com
What analysts say about Lexicon Pharmaceuticals Inc. stockTremendous gains - Autocar Professional
H.C. Wainwright Reiterates a Buy Rating on Lexicon Pharmaceuticals (LXRX) - MSN
Lexicon Pharmaceuticals: A High-Potential Biotech Play in the Diabetes Space - AInvest
10 Hot Penny Stocks to Invest in Now - Insider Monkey
Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025) - The Manila Times
Lexicon Pharmaceuticals to Present Study on Diabetic Peripheral Neuropathic Pain at ASPN 2025 Conference - Quiver Quantitative
Revolutionary Non-Opioid Drug Could Help 100M People Suffering from Diabetic Nerve Pain - Stock Titan
What makes Lexicon Pharmaceuticals Inc. stock price move sharplyTop ROI Selections - beatles.ru
Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) market cap touched US$389m last week, benefiting both private equity firms who own 48% as well as institutions - simplywall.st
Lexicon Pharmaceuticals (LXRX) Soars 16.74% on Technical Signals - AInvest
Lexicon Pharmaceuticals Defies Expectations: What Lies Ahead? - StocksToTrade
Lexicon Pharmaceuticals Granted Nasdaq Compliance Extension - The Globe and Mail
Lexicon Pharmaceuticals receives additional compliance period from Nasdaq - Investing.com
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm - ACCESS Newswire
While institutions own 28% of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), private equity firms are its largest shareholders with 48% ownership - Yahoo Finance
HC Wainwright Reaffirms Buy Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat
Congestive Heart Failure Market to Expand Significantly by 2034, States DelveInsight Report | Mesoblast, Bayer, Novo Nordisk, Lexicon Pharmaceuticals, Merck Sharp & Dohme LLC, Corthera - Barchart.com
Lexicon Pharmaceuticals (LXRX) Receives Buy Rating from HC Wainwright & Co. | LXRX Stock News - GuruFocus
H.C. Wainwright reiterates buy rating on Lexicon Pharmaceuticals stock By Investing.com - Investing.com Canada
Breakthrough: Sotagliflozin Cuts Dangerous Low Blood Sugar Events in Type 1 Diabetes Patients - Stock Titan
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) | LXRX Stock News - GuruFocus
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) - TradingView
New Clinical Data Shows Lexicon's Diabetes Drug Effective Across All Kidney Function LevelsADA Conference - Stock Titan
Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 31% - simplywall.st
Novo signs $812 million weight-loss drug license deal with US biotech Deep Apple - MarketScreener
Lexicon Pharmaceuticals surges 67% following InvestingPro’s Fair Value signal By Investing.com - Investing.com
Lexicon Pharmaceuticals at Jefferies Conference: Strategic Partnerships and Pipeline Progress - Investing.com Canada
Earnings call transcript: Lexicon Pharmaceuticals Q4 2024 beats EPS forecast By Investing.com - Investing.com UK
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Shares Bought by Northern Trust Corp - Defense World
Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times
Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential - MSN
Lexicon Pharmaceuticals' Q1 2025: Unpacking Contradictions in Trial Designs, FDA Strategies, and Partnership Plans - AInvest
Lexicon (LXRX) Advances Study on Sotagliflozin for Heart Conditions | LXRX Stock News - GuruFocus
LXRXLexicon Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan
Analysts Just Made A Noticeable Upgrade To Their Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Forecasts - simplywall.st
Earnings Update: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Just Reported And Analysts Are Boosting Their Estimates - simplywall.st
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance
Lexicon targets late 2025 Phase 3 start for pilavapadin and expands LX9851 partnership with Novo Nordisk - MSN
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2025 Earnings Call Transcript - Insider Monkey
Lexicon Pharmaceuticals Inc Stock (LXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lexicon Pharmaceuticals Inc Stock (LXRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sullivan Diane E. | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
36,810 |
| SOBECKI CHRISTOPHER J | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
203,865 |
| BARKER SAM L | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
124,459 |
| Amouyal Philippe | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
285,174 |
| DEBBANE RAYMOND | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
1,385,689 |
3.67%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):